The first parallel imports to be authorized by Finland's National Agency for Medicines are expected to become available in the third quarter of the year, following amendments to the regulations earlier this year.
These now require pharmacists to dispense the least expensive version of a branded drug, unless the prescriber specifies a market authorization holder's name as well as the product's name, reports The Pharmaceutical Journal. Finland has also now introduced generic prescribing, but the Journal says that prescribers have so far shown little enthusiasm for this option.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze